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Uterine carcinosarcoma is a rare gynecologic neoplasm with an
overall poor prognosis (Arrastia et al., 1997). The care of women
with uterine carcinosarcoma and other gynecologic cancers is often
complicated bymedical co-morbidities. However given the aggressive
nature of this malignancy, the physician frequently cannot delay sur-
gical and/or medical interventions and must balance treatment of
the underlying malignancy and management of these co-morbidities.
We describe a case of a woman with a recent history of acute cor-
onary syndrome (ACS) requiring coronary artery drug eluting stent
placement that presents for surgical treatment of a uterine carcino-
sarcoma. During her post-operative management she develops eptiﬁ-
batide induced thrombocytopenia. Eptiﬁbatide is a synthetic cyclic
heptapeptide which acts with a high afﬁnity at the platelet GPIIb/
IIIa receptor. It mitigates the pro-thrombotic cascade by competi-
tively inhibiting the interaction between ﬁbrinogen and the platelet
ﬁbrinogen receptor, resulting in inhibition of platelet aggregation
and intracoronary thrombus formation during ACS and percutaneous
coronary intervention (PCI).
The medication has also grown to be more widely used in the peri-
operative period for anticoagulation due to its short half life (2.5 h)
and the rapidity with which platelet aggregation returns to normal
(4 h) (Hodivala-Dilke et al., 1999). The typical regimen of administra-
tion is a 180 mcg/kg bolus with a 2 mcg/kg/min IV infusion (The
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ous medical co-morbidities in gynecologic oncologic patients, we pre-
sent our experience, which we believe to be the ﬁrst occurrence of
eptiﬁbatide induced thrombocytopenia in a patient with active malig-
nancy and only the second case of potential thrombosis associated
with eptiﬁbatide use, to raise awareness of these rare but serious ad-
verse drug reactions (The PURSUIT Trial Investigators, 1998).
Case presentation
A 65 year-old G0 Caucasian female was in her usual state of health
until she presented to an outside hospital with ACS. Her past medical
history was signiﬁcant for Type II diabetes mellitus, hypertension,
arthritis and a remote ovarian cystectomy for benign disease. She
had no known exposure to anticoagulant medications and no family
history of thrombosis. She subsequently underwent extraction of a
right coronary artery plaque and placement of two drug eluting
stents, during which she received aspirin, heparin, clopidogrel and
eptiﬁbatide. While hospitalized, she complained of abdominal pain.
A computed tomographic (CT) scan of the abdomen/pelvis demon-
strated a complex adnexal mass (14.3×10.3×7.9 cm) with associated
hydroureter and periaortic lymphadenopathy but no ascites. Biopsy
of an enlarged lymph node demonstrated a poorly differentiated neo-
plasm suggestive of Mullerian origin. Given her recent myocardial
infarction requiring clopidogrel, neoadjuvant chemotherapy with
taxotere and carboplatinum was initiated as an outpatient, but the
patient tolerated one dose poorly secondary to hypotension from an
acute reaction to chemotherapy administration and recalcitrant nau-
sea and fatigue.
The patient sought a second opinion at our institution, and an en-
dometrial biopsy was obtained which established the diagnosis of
uterine carcinosarcoma. Since surgery was thought to be the pre-
ferred treatment with the new diagnosis of carcinosarcoma and her
impending colonic obstruction, she was referred for pre-operative
cardiology evaluation, which included a review of her outside hospi-
tal echocardiogram, catheterization ﬁlms, and electrocardiogram as
well as an outpatient cardiology work-up with and scheduled for sur-
gery. Lower extremity venous dopplers one week prior to surgery did
not demonstrate evidence of thrombosis. Given her recent stent
placement, clopidogrel was discontinued ﬁve days prior to surgery,
and she was admitted for an eptiﬁbatide infusion (180 mcg/kg bolus
with a 2 mcg/kg/min IV infusion). Pre-eptiﬁbatide infusion blood
counts included a platelet count of 373,000 per mm3(Fig. 1 for the












Fig. 1. Trend in platelet levels during hospital stay. Various interventions are documented along with change in platelet levels in the ﬁgure.
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ing, total abdominal hysterectomy, bilateral salpingo-oophorectomy,
rectosigmoid resection with end colostomy, small bowel resection and
re-anastomosis, bilateral ureterolysis, partial cystectomy, and appen-
dectomy. Bilateral intermittent pneumatic compression devices were
used for intra-operative venous thromboembolism (VTE) prophylaxis.
Estimated blood loss was 5 l secondary to the patient's recent anti-
coagulation, extensive underlying tumor burden, and the radical dissec-
tion required to debulk themajority of the disease. During the operation
she received crystalloid, colloid, 9 U of packed red blood cells and 3 U of
fresh frozen plasma. No platelets were transfused intra-operatively, and
her immediate post-operative platelet count was 155,000 per mm3.
One unit of single donor platelets was transfused after her platelets
nadired to 61,000 per mm3 in the post-operative period.
Within 2 h of her tenure in the post-operative unit, the patient's
left lower extremity was noted to be swollen with marked poiki-
lothermia and pallor. Lower extremity venous dopplers demonstrated
diffuse VTE involving the right popliteal, gastrocnemius and soleal
veins and the left common femoral, femoral, popliteal, posterior tibial
and peroneal veins (Supplementary Figs. 1 and 2). Given the patient's
operative blood loss and increased risk of bleeding in the immediate
postoperative period, targeted tissue plasminogen activator therapy
and mechanical thrombectomy were not initiated. The patient in-
stead underwent inferior vena cava ﬁlter placement and initiation
of a bivalirudin (direct thrombin inhibitor, which is utilized as an ef-
fective anti-platelet therapy in the setting of PCI with a decreased
bleeding risk) infusion per vascular surgery (Palmerini et al., 2011).
Given her drug eluting stents, she was restarted on an eptiﬁbatide in-
fusion (2 mcg/kg/min) approximately 36 h after the diagnosis of the
thrombus.
Within 6 h of eptiﬁbatide re-initiation, she developed a profound
thrombocytopenia to 6000 per mm3 from previous platelet count of
130,000 per mm3. Both the bivalirudin and eptiﬁbatide infusions
were immediately discontinued. Work-up for disseminated intravas-
cular coagulopathy revealed a normal lactate dehydrogenase and
slightly elevated haptoglobin; peripheral smear was notable only for
profound thrombocytopenia, making pseudo-thrombocytopenia
unlikely. An anti-heparin platelet factor 4 (PF4) panel was negative.
An inherited thrombophilia work-up was also unremarkable. Over
the course of the next two days the patient received 2 U of platelets,
increasing her platelet to 28,000 per mm3. Secondary to her extensiveVTE, she was cautiously restarted on the bivalirudin infusion on post-
operative day #6
She was eventually initiated on clopidogrel on post-operative
day #8 (a thienopyridine, which blocks the interaction of ADP with a
platelet receptor thereby preventing platelet aggregation and is
employed as an agent in dual anti-platelet therapy after PCI to prevent
stent re-thrombosis) and therapeutic enoxaparin for long term anticoa-
gulation (Park et al., 2008). The use of prophylactic anti-coagulation, in-
cluding low molecular weight heparin (LMWH) and enoxaparin, was
delayed in this case secondary to the patient's initial profound thrombo-
cytopenia and blood loss. In addition the patient's thromboembolic dis-
ease developed on the day of surgery, whichwas prior to post-operative
day #1, the typical date of anti-coagulation initiation. Her platelet count
continued to increase back to her baseline of 340,000 per mm3 on post-
operative day #14 when she was discharged after meeting her post-
operative milestones.
The patient initially did well following discharge to a rehabilita-
tion facility with improvements in mobility and functional status.
She received one cycle of adjuvant taxotere and carboplatinum four
weeks post-operatively. Two weeks later a CT scan showed diffuse
metastatic disease, speciﬁcally to her ostomy site, with associated
symptomatic hemorrhage. Two months post-operatively the patient
was admitted to an outside hospital with acute mental status
changes and hypercalcemia and was placed on palliative care with
her eventual death during that hospitalization.
Discussion
Due to the growing use of drug eluting stents, the use of eptiﬁba-
tide is becoming more widespread. The Platelet Glycoprotein IIb/IIIa
in Unstable Angina: Receptor Suppression Using Integrilin Therapy
(PURSUIT) Trial demonstrated an increased incidence of profound
thrombocytopenia (plateletsb20,000 per mm3) in 0.2% of the popula-
tion receiving eptiﬁbatide compared to b0.1% of the control popula-
tion (RR 5.0; 95% CI 1.3 to 32.4) (Russell et al., 2009). A few case
reports have described a similar degree of thrombocytopenia within
2 to 24 h of eptiﬁbatide exposure (Bougie et al., 2002; The PURSUIT
Trial Investigators, 1998). Research has shown that pre-existing
drug-dependent antibodies bind platelets in the presence of the
GPIIb/IIIa inhibitor and cause profound thrombocytopenia by platelet
and megakaryocyte destruction (Greinacher et al., 2009). In addition
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that eptiﬁbatide is also associated with an increased incidence of
thrombosis. In the presence of these pre-existing drug-dependent
antibodies, like heparin, eptiﬁbatide can cause platelet secretion and
aggregation mediated through interaction of the antibody Fc region
with the platelet FcγRIIa receptor (Gao et al., 2009).
Our patient experienced an acute decrease in platelets within 6 h of
her third exposure to eptiﬁbatide indicating that eptiﬁbatide was the
most likely cause of her thrombocytopenia. She maintained her platelet
levels on re-exposure to bivalirudin, clopidogrel, aspirin and enoxaparin.
Although the combination of thrombocytopenia and thrombosis was
very concerning for HITT, an anti-heparin PF4 panel was negative. Her
clinical picture and labs did not support disseminated intravascular
coagulopathy or thrombotic thrombocytopenic purpura. Although her
tremendous clot burden could have consumed a signiﬁcant amount of
platelets, her platelet count was stable immediately before eptiﬁbatide
initiation and greater than 36 h after the incidence of clot. Consistent
with prior cases, upon discontinuation of eptiﬁbatide and initiation of
supportive therapywith platelet transfusion as necessary, she recovered
to a normal platelet count prior to discharge without adverse events.
Patients with a gynecologic malignancy are at increased risk for
VTE given their often advanced age, need for long extensive abdomi-
nal and pelvic surgeries and the inherent hypercoaguability of their
malignancy. However the rapid development of our patient's clot
and the extensive nature of her thromboembolic burden are not con-
sistent with the standard presentation of gynecologic malignancy
associated VTE. Despite an extensive clinical work-up our patient
had no identiﬁable etiology for a pro-thrombotic state except her
underlying cancer. Data regarding thrombosis associated with eptiﬁ-
batide is limited. None of the major clinical trials evaluating the
use of the drug in the setting of ACS or PCI reported the incidence
of thrombosis. Only one other case report describes the development
of thrombosis secondary to eptiﬁbatide use (The PURSUIT Trial
Investigators, 1998). Despite this limited data, given that our patient
had an abnormal presentation of VTE for a gynecologic malignancy
and negative thrombophilia work-up, we believe the clinical presen-
tation is highly suggestive of eptiﬁbatide induced thrombosis.
We present a case of both thrombocytopenia and thrombosis associ-
atedwith eptiﬁbatide use to add to the growing literature regarding this
phenomenon. Most data about this GP IIb/IIIa inhibitor is extrapolated
from its use as an anti-platelet therapy in the setting of ACS.We believe
our case is the ﬁrst to describe the phenomenon in a patient undergoing
treatment for active malignancy requiring prophylaxis against stent re-
thrombosis. In addition it is one of a few studies to describe the phe-
nomenon on second re-exposure; most cases are either on initial expo-
sure or ﬁrst re-exposure. Finally this is only the second case to describe
potential thrombosis associated with eptiﬁbatide use. Although our
patient had a number of etiologies for her extensive lower extremity
thrombosis including underlying malignancy and prolonged immobili-
ty intra-operatively during pelvic surgery and the incidence of eptiﬁba-
tide induced thrombosis appears to be rare, this case highlights the
need for caution when using eptiﬁbatide in those with an increased
pre-disposition to hypercoaguability. A recent in vitro study which
included cell cultures of thrombin, platelets and HeLa cells with and
without the addition of eptiﬁbatide demonstrated that the GPIIb/IIIa in-hibitor effectively blocked platelet GPIIb/IIIa integrin and subsequently
decreased HeLa cell transmembrane translocation and migration. This
data suggests that eptiﬁbatidemay have a role in decreasingmetastatic
spread of disease by inhibiting the aggregation of thrombin activated
platelets with cancer cells (Liu et al., 2009). As the various forms of
GPIIb/IIIa inhibitors become employed in more broad clinical settings,
such as a preventative intervention against metastatic disease, we
hope that in adding this case to the literature we can raise awareness
of this rare but potentially devastating side effect of eptiﬁbatide use.
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